Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748204 | 0.86 | HDAC6 (0.60) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL18573453 | 0.83 | RAB9A (0.60) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL3086968 | 0.80 | HDAC6 (0.85) | HDAC6KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL6477476 | 0.79 | KDM4E (0.58) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL23452076 | 0.78 | KDM4E (0.49) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL18573590 | 0.78 | NPC1 (0.62) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL6246675 | 0.77 | HDAC6 (0.72) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL18573642 | 0.77 | NPC1 (0.63) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL27141132 | 0.76 | RAB9A (0.54) | HDAC6KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL18573575 | 0.75 | HDAC6 (0.62) | HDAC6KMT2AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | claimed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | claimed |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Autophagysciences Inc. (KR) | 2018-08-30 | — | — | US | claimed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | claimed |
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | disclosed |
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-107922374-B | Novel catechol derivatives and pharmaceutical compositions containing the same | 自体吞噬科学有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Autophagysciences Inc. (KR) | 2018-08-30 | — | — | US | disclosed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034242-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 유영제약 | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | ATG7, BECN1, SLC10A1 | HDAC6 233/4885KMT2A 2781/4885ALDH1A1 396/4885 |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | BECN1, ATG7, SQSTM1 | HDAC6 213/4885KMT2A 2158/4885ALDH1A1 442/4885 |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BECN1, ATG7, TFEB | HDAC6 136/4885KMT2A 2643/4885ALDH1A1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.